Biotech investing: is there a doctor in the house?

Rudi Van den Eynde, Head of Thematic Global Equity at Candriam, answers investors’ questions about a sector where depth of specialist knowledge is a prerequisite to consistent stock selection success.

Find it fast

Get information faster with a single click

Get insights straight to your inbox